SSI Strategy published a new article in Frontiers in Medicine examining New Approach Methodologies (NAMs) from scientific, regulatory, and strategic perspectives.
Public source
Publisher name
Public post
In their latest publication in Frontiers in Medicine, our experts Sabine Poppenborg, Debra Webster & Björn Carlsson, examine New Approach Methodologies (NAMs) from scien…
Company
SSI Strategy
Building Better Biotechs
- Industry
- Business Consulting and Services
- Location
- Parsippany, US
- Company size
- 51–200 employees
About SSI Strategy
At SSI Strategy, we're strategic partners deeply invested in our clients' success. We offer a unique, adaptive approach to supporting biotech companies, integrating business acumen with deep expertise in Clinical Development & Operations, Regulatory affairs, Pharmacovigilance, Medical Affairs, Quality and more. Our agile skills and resources model allows us to adapt to your specific needs, working as an embedded team within your organization. We complement your existing teams, scaling specialized skill sets up and down as needed, while equipping them with the tools and resources to operate at peak performance. By fostering the organization you want to build, we position your full-time employees to be more successful and effective in their strengths. As your needs evolve, so does our support. We offer deep expertise, strategic insight, and a comprehensive range of services to help you navigate the challenges of bringing a therapeutic from concept to commercialization. Our mission is clear: Build better biotechs through seamless collaboration, informed decision-making, and accelerated progress.
See moreLatest activity
Latest activity from SSI Strategy
4 signals
Presence & Recognition
SSI Strategy is hosting a strong line-up of events in Boston, San Diego, Madrid, and Milan for the rest of 2026.
Research & Knowledge
SSI Strategy read six Western pharma partnering forms including Merck, Novartis, Pfizer, Sanofi, BMS, and J&J field by field.
Presence & Recognition
SSI Strategy attended the ESC Congress event in 2026.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
ScitoVation
ScitoVation published a new issue of ScitoVation Insight exploring the FDA's approach to New Approach Methodologies (NAMs) and what sponsors need to know.
Research & Knowledge
Battelle
Battelle published a blog exploring the challenges of moving New Approach Methodologies from research tools to decision-support systems.
Research & Knowledge
Simon-Kucher
Simon-Kucher published an article examining how biotechs weigh access, speed, investment, and control to choose the right path to commercialization and make limited resources work harder.
Research & Knowledge
MatTek Life Sciences
MatTek Life Sciences published an article in Microtissue Matters by Alex Armento discussing NAMs adoption and its impact on R&D.
Research & Knowledge
XCellR8